The pharmaceutical industry is experiencing significant growth in the volume and variety of data from several sources, including the R&D process, retailers, patients, and caregivers. Sales and marketing functions in the pharmaceutical industry have been leading adopters of big data technology and other functions are starting to move in that direction, especially Research and Development (R&D). The current stagnant pipeline and decline in success rates for new drugs is forcing R&D organizations to look at new ways to accelerate the pipeline of new drugs.
Broad changes in the healthcare industry including regulatory changes are also driving the pharmaceutical industry to examine various aspects of their business. In fact, The McKinsey Global Institute estimates that applying big data strategies to better inform decision making could generate up to $100 billion in value annually across various facets of the US healthcare and pharmaceutical system. The industry-leading MapR Distribution for Apache™ Hadoop® is ideally suited for a wide variety of use cases in the pharmaceutical industry, some of which are detailed below:
DNA sequencing has resulted in significant growth in the volume of data that needs to be computed. This has led to a need for a different and more scalable approach in order to improve the overall genomic research process. A leading pharmaceutical organization is using the MapR Distribution for Hadoop to achieve the following benefits:
Pharmaceutical R&D needs to innovate on the use of cutting-edge tools in order to accelerate the rate at which new drugs are discovered. These include sophisticated modeling techniques such as systems biology and high-throughput data production technologies that can highly benefit from the parallel computing framework that Hadoop provides.
Incorporating new types of data such as patient genotypes and clinical trials into the drug development process results can also help in making personalized medicine and diagnostics an integral part of the drug-development process rather than an afterthought.
Adherence is broadly defined as the degree to which a consumer takes prescribed drugs as directed. A Capgemini study reports that adherence levels drop over the course of the patient journey from 69% to 43% after the first 6 months of treatment.
The impact of adherence is significant as this leads to about $400 billion in avoidable hospitalizations. This has an impact on pharmaceutical companies as well since patients do not fill prescriptions due to lack of adherence. The usage of Hadoop can bring in a new paradigm and approach to the adherence problem by:
The business benefits of improving adherence include:
MapR delivers on the promise of Hadoop with a proven, enterprisegrade platform that supports a broad set of mission-critical and real-time production uses. MapR brings unprecedented dependability, ease-of-use and world-record speed to Hadoop, NoSQL, database and streaming applications in one unified big data platform. MapR is used by more than 500 customers across financial services, retail, media, healthcare, manufacturing, telecommunications and government organizations as well as by leading Fortune 100 and Web 2.0 companies. Amazon, Cisco, Google and HP are part of the broad MapR partner ecosystem. Investors include Lightspeed Venture Partners, Mayfield Fund, NEA, and Redpoint Ventures. MapR is based in San Jose, CA. Connect with MapR on Facebook, LinkedIn, and Twitter.